SBIR/STTR Research Award
Clinical Development of IPdR for Radiosensitization Period of Performance: 09/19/2014 - 06/18/2015
Award amount
$191,971Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Shuttle Pharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- DRXGHKX67C67
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
The objective of this fast-track SBIR Application is to advance commercialization efforts for IPdR (5-iodo-2pyrimidinone-2'-deoxyribose), a prod rug of the radiosensitizer IUdR (5-iodo-2'-deoxyuridine). In the Phase I SBIR, we will determine the scientific merit, feasibility and potential for commercialization of oral lPdR as a radiation sensitizer for use in cancer treatment. Administrative tasks will be completed to enable an IND for Shuttle Pharmaceuticals, LLC; formulation of GMP manufactured IPdR into 300 mg capsules; submission of a letter of intent (LOI) to CTEP; protocol preparation and IRB approval for the proposed Phase I clinical trial and establishment of companion diagnostics for analyzing clinical specimens from Phase I patients. The tasksdetailed for the Phase I effort are intended to facilitate an IND for IPdR for Shuttle Pharmaceuticals. PUBLIC HEALTH RELEVANCE
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TOPIC 345: PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS
- Topic 352: Cell-Based Models for Prostate Cancer Health Disparity Research - Moonshot
- IGF OT IGF PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS
- IGF OT IGF SBIR PHASE I TOPIC CELL BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH
- IGF OT IGF CLINICAL DEVELOPMENT OF IPDR FOR RADIOSENSITIZATION
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
6 SBIR/STTR records share this UEI (2014–2019). Reported award amounts total $5,531,722. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services